The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better
- Home
- Publications
- The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better
Latest News
BLADDER CANCER AWARENESS
08 May, 2024Head And Neck Cancer
08 May, 2024MELANOMA
08 May, 2024CYBER KNIFE TREATMENT IN DUBAI
08 May, 2024
Patient Appreciation
08 May, 2024
Seminar & Events
Dr Alrawi in Alandalus Hospital in Baghdad.
09 Jun, 2023Al Hurra tv interview
29 May, 2023
